Trial · NCT05770882
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
NCT05770882, Phase 1, Phase 2, Terminated, Great Novel Therapeutics Biotech & Medicals Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC). Trials, record NCT05770882. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05770882
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
- NCT number
- NCT05770882
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Chidamide, Regorafenib
- First posted
- 2023-03-16
- Last updated
- 2025-03-11
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse event (AE) | From the first day of treatment until progressive disease or death, assessed up to 12 months | To analyze the frequency, percentage of patients with study medications of adverse events |
| Primary | Maximum tolerated dose(MTD) / maximum feasible dose (MFD) | From start of treatment Cycle1 Day1 until completion of one cycle of treatment (maximum 28 days) | To assess tolerability/feasible of study medications dose |
| Primary | Pharmacokinetics profiles - (AUC0-t) | Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle) | Area under the plasma concentration-time curve from time zero to time t(AUC0-t) |
| Primary | Pharmacokinetics profiles - (AUC0-∞) | Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle) | Area under the plasma concentration-time curve from time zero to infinity(AUC0-∞) |
| Primary | Pharmacokinetics profiles - (Cmax) | Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle) | Maximum plasma concentration(Cmax) |
| Primary | Pharmacokinetics profiles - (Tmax) | Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle) | Time to maximum plasma concentration(Tmax) |
| Primary | Pharmacokinetics profiles - (T1/2) | Blood samples collected on Days 1-4 and 18-21 of Cycle 1, pre-dose and up to 72 hours post-dose (28 days/cycle) | Half-life(T1/2) |
| Primary | Objective response rate (ORR) | Objective Response Rate is assessed every 8 weeks from start of treatment until progressive disease is documented (approximately 6 months) | The percentage of patients with CR and PR of total number of analysis set |
| Primary | Progression-free survival (PFS) | From the first day of treatment until disease progression or death from any cause, assessed up to 12 months | The time from first day of dosing until the date of first objective disease progression or death |
| Secondary | Overall survival (OS) | 1 year | The time from the first day of dosing until the date of death |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05770882
GET https://conductscience.org/api/trials/v1/NCT05770882/registered